OLATEC THERAPEUTICS LLC
- Country
- πΊπΈUnited States
- Ownership
- Holding
- Established
- 2003-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.olatec.com
Clinical Trials
14
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (14 trials with phase data)β’ Click on a phase to view related trials
Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare
- Conditions
- GoutGout FlareArthritisGout AttackAcute Gout FlareJoint PainGouty Arthritis
- Interventions
- Other: Placebo Tablet
- First Posted Date
- 2022-12-20
- Last Posted Date
- 2025-05-29
- Lead Sponsor
- Olatec Therapeutics LLC
- Target Recruit Count
- 300
- Registration Number
- NCT05658575
- Locations
- πΊπΈ
University of Alabama at Birmingham, Birmingham, Alabama, United States
πΊπΈArizona Arthritis & Rheumatology Associates - Glendale, Glendale, Arizona, United States
πΊπΈArizona Arthritis & Rheumatology Associates (AARA), P.C. - Mesa, Mesa, Arizona, United States
Safety and Efficacy of Dapansutrile for Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release Syndrome
- Conditions
- Cytokine Release SyndromeCovid19
- Interventions
- Drug: placebo capsules
- First Posted Date
- 2020-09-07
- Last Posted Date
- 2023-04-13
- Lead Sponsor
- Olatec Therapeutics LLC
- Target Recruit Count
- 49
- Registration Number
- NCT04540120
- Locations
- πΊπΈ
C&R Research Services USA, Houston, Texas, United States
πΊπΈInvesclinic U.S. LLC, Fort Lauderdale, Florida, United States
πΊπΈInpatient Research Clinic, LLC, Hialeah, Florida, United States
Pilot Study of Dapansutrile Capsules in Schnitzler's Syndrome
- First Posted Date
- 2018-07-23
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Olatec Therapeutics LLC
- Target Recruit Count
- 2
- Registration Number
- NCT03595371
- Locations
- π³π±
Radboudumc, Nijmegen, Netherlands
Study of Dapansutrile Capsules in Heart Failure
- Conditions
- Systolic Heart Failure
- Interventions
- Drug: Placebo capsules
- First Posted Date
- 2018-05-23
- Last Posted Date
- 2020-01-09
- Lead Sponsor
- Olatec Therapeutics LLC
- Target Recruit Count
- 30
- Registration Number
- NCT03534297
- Locations
- πΊπΈ
Virginia Commonwealth University - Pauley Heart Center, Richmond, Virginia, United States
Phase 1 Safety and PK Study of OLT1177 Capsules
- Conditions
- Healthy Volunteers
- Interventions
- Drug: Placebo CapsulesDrug: OLT1177 Capsules
- First Posted Date
- 2014-05-09
- Last Posted Date
- 2015-03-06
- Lead Sponsor
- Olatec Therapeutics LLC
- Target Recruit Count
- 35
- Registration Number
- NCT02134964
- Locations
- πΊπΈ
J&S Studies, Inc, College Station, Texas, United States
- Prev
- 1
- 2
- Next
News
Gout Drug Pipeline Expands with 25+ Novel Therapies as Companies Target Unmet Medical Needs
The gout therapeutics pipeline has expanded significantly with over 20 companies developing 25+ novel drugs across various clinical stages, addressing critical unmet needs in gout management.